title: Alosetron: a case study in regulatory capture, or a victory for patients' rights?
authors.affiliation: Australian Financial Review, GPO Box 506, Sydney 2201, NSW, Australia. ray_128@hotmail.com
authors.forename: Ray
authors.initials: R
authors.lastname: Moynihan
mesh_terms: D002243:Carbolines / Q000009:adverse effects* / Q000600:supply & distribution; D003109:Colonic Diseases, Functional / Q000188:drug therapy*; D017277:Drug Approval; D005765:Gastrointestinal Agents / Q000009:adverse effects* / Q000600:supply & distribution; D006801:Humans; D028701:Patient Rights; D012307:Risk Factors; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D002243:Carbolines; D005765:Gastrointestinal Agents; C090840:alosetron